What Happened
- Doctors at Max Super Speciality Hospital, Saket, New Delhi, successfully treated a 41-year-old Iraqi patient diagnosed with choroidal melanoma — a rare and potentially life-threatening intraocular cancer — preserving both his eye and vision.
- The patient, who had experienced gradual loss of vision for nearly six months, was found to have a large intraocular tumour measuring approximately 9.5 × 13.5 mm — roughly the size of a small pea within the confined space of the eye.
- Treatment was carried out using plaque brachytherapy, a precision radiation technique in which a radioactive plaque is temporarily sutured onto the outer surface of the eye directly over the tumour site.
- The radioactive plaque used was a Ruthenium-106 plaque indigenously developed by the Bhabha Atomic Research Centre (BARC), enabling access to world-class treatment at a significantly lower cost than imported alternatives.
- The case highlights India's growing reputation as a destination for advanced, specialised medical care and the role of indigenous nuclear technology in healthcare applications.
Static Topic Bridges
Brachytherapy and Nuclear Technology in Medicine
Brachytherapy is a form of radiotherapy in which a radioactive source is placed in close proximity to, or directly within, the tumour. In plaque brachytherapy for ocular cancers, a small radioactive disc (plaque) is surgically sutured to the outer wall (sclera) of the eye over the tumour, left in place for several days to deliver a calculated radiation dose, and then removed. Ruthenium-106 (Ru-106) is a beta-emitting radioisotope — meaning it emits beta particles (electrons) rather than gamma rays. Beta emitters create a steep radiation gradient, delivering high doses to the tumour base while minimising exposure to adjacent healthy structures such as the retina, optic nerve, and lens. This makes Ru-106 particularly suited for smaller to medium-sized ocular tumours.
- Ru-106 is produced as a fission by-product during nuclear fuel reprocessing — BARC harvests medical-grade Ru-106 from its reprocessing cycle.
- BARC developed the indigenously manufactured Ruthenium Brachytherapy (RuBy) plaques in 2020; first clinical use was at AIIMS, New Delhi.
- Three plaque configurations are available; a dedicated plaque simulation software has also been developed.
- Brachytherapy is preferred over external beam radiation for well-localised tumours due to lower collateral dose to surrounding tissue.
- The alternative to plaque brachytherapy for choroidal melanoma is enucleation (surgical removal of the entire eye).
Connection to this news: The use of BARC's indigenous Ru-106 plaque in this surgery directly illustrates how India's nuclear technology programme translates into civilian healthcare benefits — a theme frequently tested in UPSC questions on nuclear applications beyond energy.
Choroidal Melanoma and Rare Cancers
Choroidal melanoma is the most common primary intraocular malignant tumour in adults, arising from melanocytes in the choroid — a vascular layer beneath the retina. It is rare (incidence: approximately 5–7 per million population globally) but potentially lethal if not treated promptly, as it can metastasise to the liver, lungs, and skin. If caught early, eye-conserving treatments such as plaque brachytherapy or proton beam therapy can preserve both vision and the eye. The Collaborative Ocular Melanoma Study (COMS) established that plaque brachytherapy is equivalent to enucleation in terms of survival outcomes, making eye-preservation the preferred approach for eligible tumours.
- Choroidal melanoma arises from melanocytes in the uveal tract (iris, ciliary body, choroid).
- Most common primary intraocular tumour in adults; rare — incidence ~5–7 per million globally.
- Risk factors: light skin, light eye colour, fair complexion, UV exposure.
- Metastasis occurs primarily to the liver (up to 50% of patients with large tumours).
- Treatment options: plaque brachytherapy (Ru-106 or I-125), proton beam therapy, enucleation; systemic therapy for metastatic disease.
- AIIMS and Max Super Speciality Hospital are among India's leading centres for ocular oncology.
Connection to this news: The successful preservation of vision — rather than removal of the eye — in this case directly demonstrates the clinical effectiveness of India's indigenous BARC brachytherapy technology in treating one of the most challenging rare cancers.
India's Medical Tourism — Policy, Scale, and Strategic Importance
India has emerged as a global hub for medical tourism, attracting patients from over 78 countries annually due to its combination of world-class tertiary care, English-speaking medical professionals, and costs that are a fraction of those in Western countries. According to official data, between January and April 2025, India recorded over 131,000 international medical patients — approximately 4.1% of all foreign arrivals. The Government of India has actively promoted this sector through the "Heal in India" initiative, e-medical visa and e-medical attendant visa facilities, an AYUSH visa (for wellness/traditional medicine travel, introduced 2023), and the Medical Value Travel (MVT) portal. The market was valued at approximately $6 billion and is projected to reach $13 billion by 2026, with a longer-term projection of $58 billion by 2035.
- "Heal in India" initiative: promotes India as a global destination integrating modern medicine and traditional AYUSH systems.
- E-medical visa: available for patients from eligible countries; the e-medical attendant visa covers up to two accompanying persons.
- AYUSH visa (2023): dedicated visa category for patients seeking Ayurveda, Yoga, Unani, Siddha, and Homeopathy treatment.
- Medical Value Travel (MVT) portal: one-stop digital platform for international patients.
- India's cost advantage: typically 60–90% lower than equivalent procedures in the US, UK, or Singapore.
- Top specialities attracting foreign patients: cardiac surgery, orthopaedics, oncology, organ transplants, ophthalmology.
- Delhi NCR, Mumbai, and Kerala are the leading destinations within India.
Connection to this news: The Iraq patient's case exemplifies India's medical tourism at its most compelling — advanced, rare-cancer surgery using indigenously developed nuclear medical technology, at a cost accessible to patients from developing countries who cannot afford Western alternatives.
Key Facts & Data
- Tumour type: Choroidal melanoma — most common primary intraocular malignant tumour in adults
- Tumour size: ~9.5 × 13.5 mm (approximately pea-sized within the eye)
- Treatment: Plaque brachytherapy using BARC-developed Ruthenium-106 (Ru-106) plaque
- Hospital: Max Super Speciality Hospital, Saket, New Delhi
- BARC Ru-106 plaque: indigenous product; first used clinically at AIIMS in September 2020
- Ru-106 is a beta emitter; steep radiation gradient minimises damage to healthy ocular tissue
- India's medical tourism market: ~$6 billion; projected $13 billion by 2026
- International patients (Jan–Apr 2025): 131,856 from 78+ countries
- "Heal in India" initiative promotes India as an integrated modern + AYUSH medical tourism destination
- E-medical visa and Medical Value Travel (MVT) portal facilitate international patient access